Screener
Viridian Therapeutics, Inc. VRDN Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLongTermDebtNoncurrent.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s long-term debt?
- Viridian Therapeutics, Inc. (VRDN) reported long-term debt of $113.64M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s long-term debt changed year-over-year?
- Viridian Therapeutics, Inc.'s long-term debt increased by 820.0% year-over-year, from $12.35M to $113.64M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Viridian Therapeutics, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude